Power Analytics Global's De-SPAC: What Investors Need to Know
Power Analytics Global is a private AI, analytics, and quantum-resistant security company going public through a merger with Drugs Made In America Acquisition Corp. (DMAA). The deal is live, but the setup still hinges on redemptions, financing, and whether the company can validate the revenue contracts tied to its valuation.
Power Analytics Global is a private AI, analytics, and quantum-resistant security company going public through a merger with Drugs Made In America Acquisition Corp. (DMAA). The deal is live, but the setup still hinges on redemptions, financing, and whether the company can validate the revenue contracts tied to its valuation.
Deal at a Glance
SPAC partner: Drugs Made In America Acquisition Corp.
SPAC ticker (trades now): DMAA
Implied valuation: $1.0B EV
Expected close: late Q3 2026
Est. first trading date: late Q3 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-20)
Company Overview
Power Analytics Global Corp. is described in the merger agreement as a private Delaware company focused on artificial intelligence, advanced analytics, and quantum-resistant security solutions. The company website frames it more broadly as a global technology IoT, data, visualization, and analytics platform built around next-generation energy design, asset optimization, and predictive analytics.
The business appears to be positioned as a software and solutions platform rather than a pure concept story. The filings reference patents, software source code, proprietary algorithms, AI/ML models, and quantum-resistant security IP, but they do not provide a clean revenue split, customer count, ARR, installed base, or other standard operating KPIs. Industry-wise, the deal sits in the overlap of enterprise AI, analytics, cybersecurity, and energy/IoT software, with a specific emphasis on quantum-resistant security.
The SPAC Deal
This is a de-SPAC transaction between Power Analytics Global and Drugs Made In America Acquisition Corp. (current ticker: DMAA). The headline valuation in the definitive merger agreement is a $1,000,000,000 target enterprise valuation, and DMAA’s 10-K said it expected PAGC’s valuation to be approximately $1.0 billion, subject to diligence and market conditions. The agreement also includes a $300,000,000 floor valuation if contract milestones are not met, which is a notable downside adjustment for a SPAC deal.
The trust account was approximately $241,292,436 as of March 6, 2026, but that cash is exposed to redemption risk. The merger agreement says closing cash depends on redemptions, taxes, expenses, and market conditions, and the parties are targeting a minimum cash level of $30 million, with flexibility to close at not less than $15 million. The deal has not disclosed a signed PIPE, though the agreement says DMAA may arrange one; any PIPE would dilute shareholders pro rata. On dilution, the public units were sold with one ordinary share plus one right to receive 1/8 of a share upon completion of a business combination, and the overhang is mainly from founder shares, private placement units/rights, representative shares, and any PIPE issuance. The transaction was announced in a May 5, 2026 8-K, with the merger agreement dated April 29, 2026. I did not find a filed vote date or evidence the deal has closed, so the estimated first-trading window is late Q3 2026 if the process stays on track. The combined company is expected to trade on NASDAQ or NYSE, but the post-merger ticker has not been disclosed.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The filings do not spell out a detailed use-of-proceeds schedule, but the structure suggests the usual SPAC logic: access to public equity capital, a faster path to listing than a traditional IPO, and a financing package that can include trust cash plus optional PIPE proceeds. The merger agreement also ties valuation to verified revenue contracts, which is a way to support the story with commercial traction rather than only forward-looking narrative.
For Power Analytics Global, the SPAC route also lets the company present a bespoke capital structure and valuation framework. That matters because the deal includes a valuation floor, minimum cash thresholds, and the possibility of additional financing to bridge closing conditions. In other words, the SPAC structure is doing more than just listing the company; it is also shaping the economics of the public debut.
Financial Highlights
The merger materials reviewed do not include audited PAGC revenue, loss, cash, or a full financial statement package for the target. What they do say is that the valuation framework depends on executed or substantially negotiated revenue contracts, and the agreement references a signed revenue contracts summary for FY 2026–2027, though the actual contract values were not visible in the excerpt reviewed.
Because the target’s operating financials were not disclosed in the materials reviewed, shareholders should treat any growth narrative as incomplete until the S-4/proxy shows the full pro forma picture. DMAA itself is a SPAC with no operating revenue; its disclosed cash is the trust account, which stood at approximately $241.3 million as of March 6, 2026, and about $231.15 million after the IPO and greenshoe. The key question is not just what PAGC says it can grow into, but how much trust cash survives redemptions and whether additional financing is needed to reach closing.
Risk Factors
The biggest de-SPAC-specific risk is redemption pressure. If a large share of DMAA shareholders redeem, the trust cash available to the combined company shrinks quickly, and the merger agreement explicitly conditions closing economics on net cash after redemptions, taxes, and expenses. That is why the minimum cash threshold matters so much: the deal targets at least $30 million and can close at not less than $15 million, but anything near the floor raises execution risk.
Dilution is the other major issue. Founder shares, private placement units/rights, representative shares, and any PIPE issuance all dilute public holders, and the deal does not disclose a committed PIPE size. There is also contract-validation risk because the valuation is tied to verified revenue contracts, plus standard closing risk around SEC effectiveness and exchange listing approval. Finally, the target’s financial disclosure is thin in the materials reviewed, so investors are being asked to underwrite a billion-dollar valuation without a full operating KPI set in hand.
Comparable Public Companies
The filings do not provide a formal comp table, but the disclosed business mix points to public peers in enterprise AI, analytics, and cybersecurity. The closest names by theme are Palantir (PLTR), C3.ai (AI), BigBear.ai (BBAI), CrowdStrike (CRWD), and Arqit Quantum (ARQQ) for the quantum-security angle.
As a broad read, this peer group has generally been valued on revenue growth, software margins, and strategic positioning rather than near-term earnings power. PLTR and CRWD typically trade at premium software multiples, while AI, BBAI, and ARQQ have tended to be more volatile and narrative-driven. Because the merger materials here do not disclose PAGC revenue or a company-provided comp table, any multiple comparison should be treated as a market-context reference, not a direct valuation anchor.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a classic SPAC setup with a more interesting twist: the deal is not just selling an AI story, it is also tying valuation to contract verification and setting a contractual floor if milestones are missed. That makes the setup more disciplined than many de-SPACs, but it also means shareholders should watch the S-4/proxy for the actual contract evidence, the cash-in-trust after redemptions, and whether a PIPE shows up to shore up the balance sheet.
Why it matters now is simple: the headline valuation is $1.0 billion, but the real economics will be decided by how much of the $241.3 million trust survives, how much dilution is added, and whether the company can prove the revenue base that supports the deal. Until those pieces are visible, the setup favors careful scrutiny over blind enthusiasm.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
